Stocks · News reference

Karyopharm Therapeutics Submits sNDA To FDA Seeking Accelerated Approval For XPOVIO In Combination With Ruxolitinib For Patients With Myelofibrosis

Aug 31, 2026, 11:32 AMBenzinga Newsdesk

– sNDA Submitted under the Accelerated Approval Pathway; Priority Review Requested –NEWTON, Mass., Aug. 31, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

KPTI

Source: benzinga
Observed: Aug 31, 2026, 11:32 AM
Checked: Aug 31, 2026, 11:32 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaOct 14, 2026, 11:34 AMBenzinga Newsdesk
Karyopharm Therapeutics Extends Forbearance Period To October 15
As previously disclosed in the Current Report on Form 8-K filed by Karyopharm Therapeutics Inc. (the "Company") on September 11, 2026, the Company entered into a Forbearance Agreement and Limited Waiver to
KPTI
SEC EDGAROct 14, 2026, 11:30 AMSEC EDGAR
8-K filing — Karyopharm Therapeutics Inc. (KPTI)
Filed: 2026-10-14 AccNo: 0001193125-26-421025 Size: 136 KB Item 8.01: Other Events
KPTI
BenzingaSep 11, 2026, 5:44 PMBenzinga Newsdesk
Karyopharm Therapeutics shares are trading lower after the company announced a Forbearance Agreement and Limited Waiver to gain time to advance its myelofibrosis program, negotiate with lenders, explore strategic options, or raise equity.
KPTI
BenzingaSep 11, 2026, 11:51 AMBenzinga Newsdesk
Karyopharm Therapeutics Signs Forbearance Agreement, Limited Waiver To Indentures For Additional Time To Advance Its Myelofibrosis Program; Did Not Pay $15.8M Due Under Sept. 10 Credit Agreement
https://www.sec.gov/ix?doc=/Archives/edgar/data/1503802/000119312526388621/d94769d8k.htm
KPTI

Karyopharm Therapeutics Submits sNDA To FDA Seeking Accelerated Approval For XPOVIO In Combination With Ruxolitinib For Patients With Myelofibrosis

Connected Markets

Related Headlines

Karyopharm Therapeutics Extends Forbearance Period To October 15

8-K filing — Karyopharm Therapeutics Inc. (KPTI)

Karyopharm Therapeutics shares are trading lower after the company announced a Forbearance Agreement and Limited Waiver to gain time to advance its myelofibrosis program, negotiate with lenders, explore strategic options, or raise equity.

Karyopharm Therapeutics Signs Forbearance Agreement, Limited Waiver To Indentures For Additional Time To Advance Its Myelofibrosis Program; Did Not Pay $15.8M Due Under Sept. 10 Credit Agreement